📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
42 announcements match the current filters (relevance ≥ 5).
ICRA Reaffirms [ICRA]A (Stable) Rating for Rs 304.15 Cr Bank Facilities
ICRA has reaffirmed Krsnaa Diagnostics' long-term rating at [ICRA]A with a Stable outlook and its short-term rating at [ICRA]A1. The total rated bank facilities amount to Rs 304.15 crore, which includes Rs 166.60 crore in long-term and Rs 137.55 crore in short-term limits. This rated amount represents approximately 57% of the company's total debt of Rs 531 crore. The rating action includes assignments for enhanced amounts, indicating the company is securing higher credit limits to support its expansion in Rajasthan and Maharashtra.
Confidence: HIGH
What changedICRA has reaffirmed the company's credit ratings while extending the coverage to an increased total facility amount of Rs 304.15 crore.
Why it mattersMaintaining an 'A' rating ensures the company can continue to access debt at competitive rates, which is vital for its capital-intensive business model of setting up diagnostic centers under government tenders.
Total Rated Amount: Rs 304.15 CrLong-term Rating: [ICRA]A (Stable)Short-term Rating: [ICRA]A1Rated Debt vs Total Debt: ~57%Total Debt: Rs 531 Cr
📅 Short termThe reaffirmation provides stability and confirms that the company's credit profile remains healthy despite recent stock price pressure.
📈 Long termThe enhanced limits for bank guarantees support the company's long-term strategy of aggressive expansion in the PPP segment across new states.
⚠ Risk flags
- High concentration of receivables from government health departments
- Stretched receivables in Himachal Pradesh and Karnataka
Key Highlights
Total bank facilities rated by ICRA amount to Rs 304.15 crore
Long-term rating reaffirmed at [ICRA]A (Stable) for Rs 166.60 crore of fund-based limits
Short-term rating reaffirmed at [ICRA]A1 for Rs 137.55 crore of non-fund based limits (Bank Guarantees)
Rated facilities cover approximately 57% of the company's total debt of Rs 531 crore
Ratings assigned for enhanced amounts in term loans (Rs 62.15 Cr) and bank guarantees (Rs 137.55 Cr)
👀 What to Watch
Monitor the company's ability to convert the enhanced bank guarantee limits into successful PPP project executions, particularly the large Rajasthan contract which is key to FY26 growth.
Krsnaa Diagnostics Seeks Approval for Director Appointments and ₹50 Lakh Remuneration Cap
Krsnaa Diagnostics has issued a postal ballot notice to seek shareholder approval for the re-appointment of Mr. Chetan Desai for a second 5-year term and the appointment of two new Independent Directors for 2-year terms. The company is also proposing a new remuneration structure for Independent Directors, involving a commission of up to 1% of net profits, capped at a maximum of ₹50 lakhs annually starting FY 2026-27. The e-voting process is scheduled to take place between June 05 and July 04, 2026, following the cut-off date of May 29, 2026.
Key Highlights
Re-appointment of Mr. Chetan Desai as Independent Director for a 5-year term ending April 2031.
Appointment of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors for 2-year terms.
Proposed commission for Independent Directors capped at 1% of net profits or a maximum of ₹50,00,000 per year.
E-voting period set from June 05, 2026, to July 04, 2026.
Resolutions include approval for Mr. Chetan Desai to continue directorship beyond the age of 75 years.
👀 What to Watch
Investors should review the profiles of the new director appointees and ensure the proposed commission-based remuneration is aligned with the company's long-term profitability and governance standards.
Krsnaa Diagnostics FY26 PAT Hits ₹101 Cr; Q4 PAT Surges 101% YoY with Improved Receivables
Krsnaa Diagnostics reported a resilient FY26 with total revenue of ₹7,728 million and an EBITDA of ₹2,149 million (28% margin). The company achieved a significant milestone in Q4 FY26 with PAT growing 101% YoY to ₹417 million, supported by the highest quarterly collection in its history at ₹1,580 million. Management highlighted a reduction in Days Sales Outstanding (DSO) from 155 to 139 days, addressing historical concerns regarding working capital. With a ₹5,000 million capex deployment, the company claims a long-term revenue visibility of ₹6,000 to ₹7,000 crores over the next 5-7 years.
Key Highlights
FY26 Revenue stood at ₹7,728 million with a 12% 5-year CAGR, outperforming the industry average of 8%.
Q4 PAT grew by 101% YoY to ₹417 million, while Q4 EBITDA margins remained strong at 29%.
DSO improved significantly to 139 days from 155 days in Q3, reflecting tighter working capital management.
Retail diagnostics now contributes 8% of total revenue, with a network of 3,500+ touchpoints across 5 states.
The company is deploying ₹5,000 million in capex, primarily for Rajasthan expansion and CT/MRI centers, targeting 200+ centers.
👀 What to Watch
Investors should view the improvement in DSO and record collections as a major positive for the PPP-heavy model. Monitor the scale-up of the Rajasthan project and the retail segment's progress toward double-digit contribution for margin expansion.
Krsnaa Diagnostics Q4 FY26 PAT Doubles to ₹417 Mn; Retail Revenue Surges 147% YoY
Krsnaa Diagnostics reported a steady 4% YoY revenue growth in Q4 FY26, reaching ₹1,926 million, while PAT surged 102% to ₹417 million, significantly aided by a ₹221.75 million fair valuation gain. The company's retail segment showed exceptional momentum, with revenue increasing 147% YoY to ₹158 million and its contribution to total revenue rising from 3% to 8%. For the full year FY26, revenue grew 8% to ₹7,728 million with EBITDA margins improving to 28%. The company continues to leverage its PPP infrastructure to scale its retail presence while maintaining a massive 70-95% price advantage over competitors.
Key Highlights
Q4 FY26 PAT grew 102% YoY to ₹417 million, including a ₹221.75 million fair valuation gain from investment in Apulki Healthcare.
Retail segment revenue jumped 147% YoY to ₹158 million, with patient count increasing from 0.09 million to 0.15 million.
Full-year FY26 EBITDA stood at ₹2,149 million (up 10% YoY) with margins expanding by 69 bps to 28%.
Network expanded to 190 CT/MRI centers and 4,700+ collection centers, serving 19.8 million patients in FY26.
Maintains extreme cost leadership with tests like Vitamin B12 priced at ₹69, approximately 95% lower than market competitors.
👀 What to Watch
Investors should focus on the rapid scaling of the high-margin retail segment and the execution of the Rajasthan pathology project. While the PAT jump includes one-off gains, the underlying operational efficiency and retail pivot provide a strong long-term growth narrative.
Krsnaa Diagnostics to Host Q4 & FY26 Post Earnings Conference Call on May 26, 2026
Krsnaa Diagnostics Limited has scheduled its post-earnings conference call for Tuesday, May 26, 2026, at 12:30 PM IST. The management will discuss the financial performance for the quarter and full year ended March 31, 2026. The session will include a presentation followed by an interactive Q&A for analysts and institutional investors. Transcripts and audio recordings will be published on the company's website subsequently.
Key Highlights
Conference call scheduled for May 26, 2026, at 12:30 Hrs IST.
Discussion to cover financial results for the quarter and year ended March 31, 2026.
Management will conduct an interactive Question and Answer session following the results briefing.
Audio recordings and transcripts will be accessible on the company's official website.
👀 What to Watch
Investors should monitor the call for management commentary on margin sustainability and the status of new PPP (Public-Private Partnership) project executions.
Krsnaa Diagnostics Receives Income Tax Demand Notices Totaling ₹11.31 Crore
Krsnaa Diagnostics has been served with income tax demand notices for the assessment years 2018-19 and 2019-20, amounting to a total of ₹11.31 crore including interest. These orders follow a search operation conducted by the Income Tax Department in July 2022. The company has already challenged these assessment orders before appellate and judicial forums, expressing confidence in its legal position. While the amount is currently treated as a contingent liability, the company will evaluate the need for provisioning under Ind AS 37.
Key Highlights
Total income tax demand of ₹11,30,54,699 raised for two assessment years.
Specific demands include ₹4.04 crore for AY 2018-19 and ₹7.27 crore for AY 2019-20.
The company has already initiated legal appeals and is contesting the orders on merit.
Management confirms no operational disruption despite the ongoing tax litigation.
The disclosure was delayed due to an internal compliance review after external consultants handled the initial litigation.
👀 What to Watch
Investors should monitor the outcome of the appellate proceedings as a final adverse ruling would impact the company's cash reserves and net profit. The ₹11.31 crore demand is significant but manageable for a company of this scale, provided no further liabilities arise from other assessment years.
Krsnaa Diagnostics Appoints Interim CFO and Overhauls Board with New Independent Directors
Krsnaa Diagnostics has announced a major leadership reshuffle, including the appointment of Mr. Chandra Prakash Singh as Interim CFO effective April 17, 2026. The board is adding significant expertise with new Independent Directors Raju Venkatraman (ex-Medall Healthcare) and Lilian Jessie Paul (PB Fintech board member) for two-year terms. These changes coincide with the departure of Whole-time Director Ms. Pallavi Bhatevara and two other directors as their tenures conclude in April 2026. The company has also reconstituted all major board committees, including Audit and Risk Management, to align with the new leadership structure.
Key Highlights
Mr. Chandra Prakash Singh appointed as Interim CFO effective April 17, 2026, bringing 28 years of finance and IPO experience.
New Independent Directors Raju Venkatraman and Lilian Jessie Paul join for 2-year terms starting April 25, 2026.
Whole-time Director Ms. Pallavi Bhatevara and two Independent Directors to exit upon tenure completion in April 2026.
Mr. Chetan Desai re-appointed as Independent Director for a subsequent 5-year term until April 2031.
Complete reconstitution of Audit, NRC, CSR, Stakeholders, and Risk Management committees effective April 25, 2026.
👀 What to Watch
Investors should monitor the transition to a permanent CFO and observe if the new board composition leads to any shifts in strategic direction or operational efficiency.
Krsnaa Diagnostics Overhauls Board and Appoints Interim CFO Chandra Prakash Singh
Krsnaa Diagnostics has announced a significant leadership transition, appointing two new Independent Directors, Mr. Raju Venkatraman and Ms. Lilian Jessie Paul, for two-year terms starting April 25, 2026. Simultaneously, Mr. Chandra Prakash Singh, a finance veteran with 28 years of experience, has been named Interim CFO effective April 17, 2026. The company also confirmed the re-appointment of Mr. Chetan Desai for a five-year term and the exit of three directors, including Whole-time Director Ms. Pallavi Bhatevara, upon completion of their tenures. These changes include a full reconstitution of key board committees to strengthen governance.
Key Highlights
Appointment of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors for 2-year terms.
Mr. Chandra Prakash Singh appointed as Interim CFO, bringing 28 years of experience in finance and IPOs.
Re-appointment of Mr. Chetan Desai as Independent Director for a 5-year term until April 2031.
Cessation of three directors, including Whole-time Director Ms. Pallavi Bhatevara, effective April 2026.
Reconstitution of Audit, Risk Management, and Nomination committees effective April 25, 2026.
👀 What to Watch
Investors should monitor the transition to a permanent CFO to ensure long-term financial leadership stability. The addition of seasoned independent directors is a positive sign for corporate governance and strategic oversight.
Krsnaa Diagnostics Overhauls Board; Appoints New Independent Directors and Interim CFO
Krsnaa Diagnostics has announced a significant restructuring of its leadership and governance framework effective April 2026. The company has appointed Mr. Raju Venkatraman (Founder of Medall Healthcare) and Ms. Lilian Jessie Paul as Independent Directors for two-year terms, while re-appointing Mr. Chetan Desai for five years. Concurrently, Mr. Chandra Prakash Singh, a finance veteran with 28 years of experience, has been named Interim CFO. These changes coincide with the completion of tenures for three existing directors, including Whole-time Director Ms. Pallavi Bhatevara.
Key Highlights
Appointment of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors for 2-year terms starting April 25, 2026.
Re-appointment of Mr. Chetan Desai as Independent Director for a subsequent 5-year term until April 2031.
Mr. Chandra Prakash Singh appointed as Interim CFO effective April 17, 2026, bringing 28 years of experience in finance and IPOs.
Cessation of three directors, including Whole-time Director Ms. Pallavi Bhatevara, effective April 24-25, 2026, upon completion of their tenures.
Full reconstitution of five board committees including Audit, Risk Management, and Nomination and Remuneration.
👀 What to Watch
Investors should view the addition of experienced healthcare and marketing professionals to the board as a positive step for governance. However, they should monitor the appointment of a permanent CFO to ensure long-term financial leadership stability.
Krsnaa Diagnostics Shareholders Approve Re-appointment of Executive Chairman for 5 Years
Krsnaa Diagnostics Limited has announced the successful passing of a postal ballot resolution for the re-appointment of Mr. Rajendra Khivraj Mutha as Executive Chairman. The resolution received overwhelming support, with 99.9951% of votes cast in favor of the 5-year term. This move ensures leadership continuity and stability for the diagnostic services provider. The voting process concluded on April 16, 2026, with negligible opposition from shareholders, indicating strong institutional and retail confidence in the current leadership.
Key Highlights
Mr. Rajendra Khivraj Mutha re-appointed as Executive Chairman for a five-year tenure
Resolution passed with 19,451,298 votes in favor, representing 99.9951% of total valid votes
Opposition was minimal, with only 952 votes (0.0049%) cast against the resolution
The voting results were verified by Scrutinizer Dinesh Shivnarayan Birla and reported on April 16, 2026
👀 What to Watch
The high approval rating reflects strong shareholder trust in the existing management. Investors should view this as a sign of leadership stability and continuity in the company's strategic direction.
Krsnaa Diagnostics Shareholders Approve Re-appointment of Executive Chairman with 99.99% Majority
Krsnaa Diagnostics Limited has successfully passed an ordinary resolution via postal ballot for the re-appointment of Mr. Rajendra Khivraj Mutha as Executive Chairman. The resolution received overwhelming support, with 99.99% of the votes cast in favor of the proposal. This appointment is set for a term of five consecutive years, ensuring leadership stability at the helm of the company. The voting process concluded on April 16, 2026, with the results verified by an independent scrutinizer.
Key Highlights
Mr. Rajendra Khivraj Mutha re-appointed as Executive Chairman for a 5-year term.
Resolution passed with 19,451,298 votes in favor, representing 99.9951% of total votes.
Only 952 votes (0.0049%) were cast against the re-appointment.
The remote e-voting process concluded on April 16, 2026, with zero invalid votes recorded.
👀 What to Watch
The overwhelming shareholder support indicates strong confidence in the current leadership; investors should view this management continuity as a positive sign for the company's long-term strategic execution.
Krsnaa Diagnostics Allots INR 430 Crore NCDs to Asian Development Bank
Krsnaa Diagnostics has successfully allotted 43,000 Non-Convertible Debentures (NCDs) worth INR 430 crore to the Asian Development Bank (ADB) on a private placement basis. These unlisted, secured NCDs carry a coupon rate of 7.790% per annum with a tenure of seven years. The repayment is structured in 13 equal half-yearly installments starting six months from the allotment date. This significant capital infusion from a prestigious multilateral institution like ADB provides the company with long-term growth capital at a competitive interest rate.
Key Highlights
Allotment of INR 430 crore worth of NCDs to Asian Development Bank (ADB)
Fixed interest rate of 7.790% per annum payable half-yearly
Long-term tenure of 7 years with final maturity on February 23, 2033
Repayment via 13 equal installments commencing 6 months from allotment
NCDs are secured against identified assets of the company
👀 What to Watch
Investors should view this as a strong validation of the company's business model by a global institution. The long-term funding at a sub-8% rate is favorable for expansion; monitor the deployment of these funds into high-RoE diagnostic projects.
Krsnaa Diagnostics Re-appoints Rajendra Mutha as Executive Chairman for 5-Year Term
The Board of Krsnaa Diagnostics has approved the re-appointment of Mr. Rajendra Mutha as Executive Chairman for a second five-year term. This new term will commence on April 26, 2026, and extend until April 25, 2031, ensuring leadership continuity for the company. Mr. Mutha brings over 20 years of experience in the pharmacy and diagnostics sectors to the role. The re-appointment is subject to shareholder approval via a postal ballot process.
Key Highlights
Re-appointment of Mr. Rajendra Mutha as Executive Chairman for a 5-year term
New term effective from April 26, 2026, to April 25, 2031
Mr. Mutha possesses over 20 years of specialized expertise in pharmacy and diagnostics
Decision is subject to final approval by shareholders through a postal ballot
Board meeting concluded at 21:10 Hrs on February 22, 2026
👀 What to Watch
Investors should view this as a positive sign of leadership stability and continuity in strategic direction. No immediate action is required as this is a routine re-appointment of a key founder-leader.
Krsnaa Diagnostics Re-appoints Rajendra Mutha as Executive Chairman for 5-Year Term
The Board of Directors of Krsnaa Diagnostics has approved the re-appointment of Mr. Rajendra Mutha as Executive Chairman for a five-year term starting April 26, 2026. Mr. Mutha, who has over 20 years of experience in the pharmacy and diagnostics sector, will lead the company until April 25, 2031. This move ensures leadership continuity and stability for the company's strategic vision. The appointment is subject to shareholder approval through a postal ballot process.
Key Highlights
Re-appointment of Mr. Rajendra Mutha as Executive Chairman for a consecutive term of 5 years.
The new term is effective from April 26, 2026, through April 25, 2031.
Mr. Mutha brings over 20 years of industry expertise and leads the company's strategic and CSR initiatives.
The decision is subject to final approval from shareholders via postal ballot.
👀 What to Watch
Investors should view this as a positive sign of leadership stability and continuity. No immediate action is required as this maintains the current management structure for the long term.
Krsnaa Diagnostics Q3 FY26 Revenue Up 4% to ₹181 Cr; Recovers ₹130 Cr in Pending Dues
Krsnaa Diagnostics reported a modest 4% YoY revenue growth to ₹1,812 million in Q3 FY26, impacted by seasonal factors and strategic operational pauses to recover government receivables. The company successfully recovered over ₹130 crores during the quarter, significantly improving its cash position and working capital discipline. The B2C segment showed strong momentum with an 8x YoY increase in retail revenue, while the company also expanded into tertiary care with its first PPP-based hospital in Pune. Despite margin pressure from expansion costs like the Rajasthan pathology rollout, management remains confident in the long-term scalability of the PPP model.
Key Highlights
Revenue from operations stood at ₹1,812 million, representing a 4% year-on-year growth.
Successfully recovered over ₹130 crores in long-pending government dues, strengthening the cash position.
Retail (B2C) revenue grew 8x year-on-year, indicating successful diversification beyond PPP contracts.
Network expanded to 190 CT/MRI centers and over 4,000 collection centers across 18 states and UTs.
Launched India's first PPP-based cancer and cardiac care hospital in Pune under the Apulki brand.
👀 What to Watch
Investors should monitor the stabilization of margins as the Rajasthan pathology rollout matures and the B2C segment scales. The significant improvement in cash collections is a positive sign for working capital health, which has historically been a concern for PPP-heavy models.
Krsnaa Diagnostics Q3 FY26 Revenue Up 4%, Retail Business Grows 8x YoY
Krsnaa Diagnostics reported a 9% YoY increase in 9M FY26 revenue to ₹5,802 million, while Q3 FY26 revenue grew 4% to ₹1,812 million. A standout performer was the retail segment, which saw an 8-fold revenue jump to ₹177 million, now contributing 10% to the total group revenue compared to just 1% a year ago. The company maintained steady EBITDA margins at 28% for the nine-month period despite ongoing investments in the Rajasthan pathology project. Expansion remains a key focus with the launch of the first Apulki Healthcare Hospital and a significant increase in diagnostic touchpoints to 3,101.
Key Highlights
9M FY26 Revenue grew 9% YoY to ₹5,802 mn with EBITDA margins improving by 92 bps to 28%.
Retail segment revenue surged ~8x YoY to ₹177 mn, increasing its contribution to total revenue from 1% to 10%.
Network expanded to 190 CT/MRI centres and 4,034 collection centres, maintaining a 75%+ bid win ratio in PPP projects.
Operationalized the first Apulki Healthcare Hospital, a 150-bed PPP facility for cancer and cardiac care in Pune.
Maintains a significant price advantage, offering services at 50-70% lower than market rates while sustaining industry-standard margins.
👀 What to Watch
Investors should focus on the rapid scaling of the retail business and the successful execution of the Rajasthan project as key growth drivers. The company's ability to maintain 28% EBITDA margins while offering disruptive pricing makes it a strong player in the affordable diagnostics space.
Krsnaa Diagnostics Q3 Revenue Up 4% YoY; Strong Cash Recovery of ₹130 Cr
Krsnaa Diagnostics reported a modest 4% YoY revenue growth to ₹1,812 mn for Q3 FY2026, while PAT declined by 21% YoY to ₹152 mn due to seasonal softness and front-loaded costs for the Rajasthan project. A significant highlight was the recovery of ₹130 crore in cash, primarily from government receivables, which significantly improves working capital efficiency. The company is also diversifying into tertiary care through Apulki Healthcare, launching a 150-bed hospital in Pune. Management expects the Rajasthan Pathology Project to drive significant revenue growth starting next fiscal year.
Key Highlights
Q3 FY26 Revenue grew 4% YoY to ₹1,812 mn, while 9M FY26 Revenue rose 9% to ₹5,802 mn.
PAT for the quarter decreased 21% YoY to ₹152 mn, impacted by seasonal factors and Rajasthan project readiness costs.
Achieved significant cash recovery of over ₹130 crore during Q3, which is ₹100 crore higher YoY.
Launched the first 150-bed PPP-based cancer and cardiac hospital in Pune under Apulki Healthcare.
The Rajasthan Pathology Project is on track with meaningful revenue contribution expected from FY2027.
👀 What to Watch
Investors should monitor the execution of the Rajasthan project and the ramp-up of the new Apulki hospital venture as these are key growth drivers. The strong cash recovery addresses historical concerns regarding government receivables, making the long-term investment case more robust despite short-term margin pressure.
Krsnaa Diagnostics Q3 FY26 PAT Drops 23.6% YoY to ₹164.9M; Revenue Down 3.5%
Krsnaa Diagnostics reported a weak performance for Q3 FY26, with standalone revenue declining 3.5% YoY to ₹1,594.32 million. Net profit saw a significant drop of 23.6% YoY, falling to ₹164.92 million from ₹216.00 million in the previous year's corresponding quarter. On a sequential basis, the performance was even softer, with revenue and PAT down 12.8% and 29% respectively compared to Q2 FY26. Furthermore, the company is currently contesting a substantial Income Tax demand of ₹513.86 million across multiple assessment years.
Key Highlights
Standalone Revenue from operations fell 3.5% YoY to ₹1,594.32 million in Q3 FY26.
Net Profit (PAT) declined 23.6% YoY to ₹164.92 million from ₹216.00 million in Q3 FY25.
9M FY26 revenue grew marginally by 2.1% YoY to ₹5,179.29 million, while 9M PAT fell 4% to ₹592.93 million.
The company is contesting an Income Tax demand of ₹513.86 million and has paid ₹102.77 million under protest.
Basic EPS for the quarter decreased to ₹5.08 from ₹6.69 in the same period last year.
👀 What to Watch
The results indicate a slowdown in growth and margin pressure which may weigh on the stock price in the short term. Investors should closely monitor management's explanation for the revenue dip and the progress of the ongoing tax litigation.
Krsnaa Diagnostics Q3 PAT Falls 23.6% YoY to ₹164.9 Mn; Revenue Down 3.5%
Krsnaa Diagnostics reported a weak set of standalone results for Q3 FY2026, with revenue declining 3.5% YoY to ₹1,594.32 million. Profit After Tax (PAT) saw a sharp decline of 23.6% YoY, falling to ₹164.92 million from ₹216.00 million in the previous year. On a sequential basis, the performance was even more subdued, with revenue and PAT dropping 12.8% and 29.0% respectively compared to Q2 FY2026. Furthermore, the company is currently litigating an Income Tax demand of ₹513.86 million across multiple assessment years.
Key Highlights
Standalone Revenue from operations decreased by 3.5% YoY to ₹1,594.32 million in Q3 FY26.
Standalone Profit After Tax (PAT) dropped significantly by 23.6% YoY to ₹164.92 million.
Total expenses for the quarter stood at ₹1,420.05 million, leading to a contraction in profit margins compared to the previous year.
The company is contesting an Income Tax demand of ₹513.86 million and has paid ₹102.77 million under protest.
For the nine-month period ended Dec 31, 2025, revenue grew marginally by 2.1% YoY while PAT declined by 4%.
👀 What to Watch
Investors should exercise caution as the company shows signs of growth stagnation and margin pressure both on a YoY and QoQ basis. The ongoing tax dispute involving over ₹500 million remains a key monitorable risk factor.
Krsnaa Diagnostics CFO Pawan Daga Resigns After 5-Year Tenure
Krsnaa Diagnostics Limited has announced the resignation of Mr. Pawan Daga from the position of Chief Financial Officer, effective January 19, 2026. Mr. Daga served the company for five years, a period during which the management credits him for contributing to the firm's growth. The resignation is attributed to personal and professional priorities. The company must now identify a successor to lead its financial operations and maintain investor confidence.
Key Highlights
Mr. Pawan Daga resigns as Chief Financial Officer (CFO) effective January 19, 2026
The outgoing CFO completed a tenure of 5 years with the company
Resignation cited as being due to personal and professional priorities
Announcement made on January 15, 2026, providing a very short 4-day transition period
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding the appointment of a new CFO to ensure leadership continuity. The short notice period between the announcement and the exit date is a point for cautious observation.
